Track Lantern Pharma Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Lantern Pharma Inc. LTRN Open Lantern Pharma Inc. in new tab

3.00 USD
EPS
-1.57
P/B
5.16
ROE
-157.37
Beta
2.10
Target Price
20.00 USD
Lantern Pharma Inc. logo

Lantern Pharma Inc.

🧾 Earnings Recap – Q3 2025

Lantern Pharma achieved significant clinical and regulatory milestones in Q3 2025, particularly with the successful Phase Ia trial of LP-184, which demonstrated a 48% clinical benefit rate in evaluable cancer patients.

  • LP-184's Phase Ia trial met all primary endpoints, with notable tumor reductions in patients with specific DNA damage repair mutations.
  • Starlight Therapeutics received favorable guidance from the FDA for its planned pediatric CNS cancer trial, combining LP-184 with spironolactone.
  • Preliminary Phase II data from the LP-300 HARMONIC trial was presented, with a comprehensive update expected in December.
  • Lantern is advancing LP-184 into targeted Phase Ib/II trials across four significant oncology indications, with a potential market exceeding $7 billion.
  • The RADR AI platform demonstrated commercial readiness, with viable modules for licensing to biopharma partners.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 12, 2026
EPS-1.57
Book Value0.58
Price to Book5.16
Debt/Equity1.71
% Insiders17.150%
Estimates
Forward P/E-1.49
Forward EPS-2.02
Target Mean Price20.00

DCF Valuation

Tweak assumptions to recompute fair value for Lantern Pharma Inc. (LTRN)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Lantern Pharma Inc. Logo Lantern Pharma Inc. Analysis (LTRN)

United States Health Care Official Website Stock

Is Lantern Pharma Inc. a good investment? Lantern Pharma Inc. (LTRN) is currently trading at 3.00 USD. Market analysts have a consensus price target of 20.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: Lantern Pharma Inc. is expected to release its next earnings report on Aug. 12, 2026. The market consensus estimate for Forward EPS is -2.02.

Investor FAQ

Does Lantern Pharma Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Lantern Pharma Inc.?

Lantern Pharma Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 12, 2026. The company currently has a trailing EPS of -1.57.

Company Profile

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Exchange Ticker
NCM (Australia) LTRN

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion